Compare Five Below Inc (FIVE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Five Below Inc trades at $200.15 (market cap $10.67B), while Vertex Pharmaceuticals Incorporated trades at $486.39 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.3× Five Below Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| FIVE | VRTX | |
|---|---|---|
Market Cap | $10.67B | $121.09B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $529.59 |
52-Week Low | $131.94 | $366.54 |
Enterprise Value | $11.56B | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $200.59, up 3.87% today, with a bullish technical signal despite mixed moving averages. The company shows strong revenue growth, rising from $2.8B in 2022 to $3.88B in 2025, and has consistently beaten earnings expectations in recent quarters. Positive sentiment is driven by store expansion and digital marketing initiatives, with 60% of analysts rating it a Buy.
The outlook is favorable with a consensus price target of $252.09, implying 26% upside, supported by robust growth projections. Risks include competitive pressures and execution challenges in expansion. Net cash flow improved to $152M in 2025, but profit margins have fluctuated, requiring monitoring of cost management.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
